Optimi Health Corp. (NASDAQ:OPTH) Stock Short Interest Rises 109.1%
by Teresa Graham · The Cerbat GemOptimi Health Corp. (NASDAQ:OPTH – Get Free Report) saw a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 20,500 shares, a growth of 109.1% from the August 31st total of 9,806 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 91,023 shares, the short-interest ratio is currently 0.2 days.
Analysts Set New Price Targets
OPTH has been the topic of several recent research reports. Weiss Ratings upgraded Optimi Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Wall Street Zen upgraded shares of Optimi Health to a “hold” rating in a report on Saturday, July 25th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce”.
Check Out Our Latest Stock Analysis on Optimi Health
Optimi Health Price Performance
Optimi Health stock traded down $0.07 during mid-day trading on Tuesday, reaching $4.78. 43,175 shares of the company were exchanged, compared to its average volume of 65,727. The company has a market cap of $27.39 million and a price-to-earnings ratio of -6.29. The firm’s fifty day simple moving average is $4.82. Optimi Health has a 12 month low of $4.00 and a 12 month high of $6.40. The company has a current ratio of 0.06, a quick ratio of 0.03 and a debt-to-equity ratio of 0.04.
Optimi Health Company Profile
Optimi Health Corp. is a Canadian life sciences company focused on the development, production and distribution of psychedelic compounds and related products. The company’s activities are centered on psilocybin-based products and other emerging psychedelic formulations intended for potential therapeutic, research and experiential applications.
Optimi Health operates from Canada and has developed capabilities for the cultivation, extraction, formulation and processing of psychedelic and functional mushroom products.
See Also
- Five stocks we like better than Optimi Health
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?